Develops and commercialises VMX-C001, a modified recombinant Factor X that rapidly restores coagulation in patients taking Factor Xa inhibitors who experience severe bleeding.
VarmX
Details
- LSH Companies
Emmy Noetherweg 2, 2333 BK, Leiden
Develops and commercialises VMX-C001, a modified recombinant Factor X that rapidly restores coagulation in patients taking Factor Xa inhibitors who experience severe bleeding.
Emmy Noetherweg 2, 2333 BK, Leiden